Canoa Inc. to Acquire Privately-Held ProSolus Inc., Accelerating Transdermal Patch Drug Delivery Product Development MIAMI, Florida, August 02, 2019 – Canoa Inc. (“Canoa”), a Delaware corporation with a focus on healthcare and pharmaceuticals, today announced that it has agreed to acquire ProSolus® Inc. (“ProSolus”), from Mission Pharmacal® Company, in an all-cash transaction. ProSolus is a…
We’re transforming topical patches and transdermal delivery systems.
By developing or in-licensing transdermal patches in a variety of therapeutic categories, our development portfolio includes pain management, cardiovascular, and neurologic care.
What We Do
ProSolus, Inc. delivers sophisticated transdermal and topical patches, customized to exceed your expectations. We formulate, develop, and manufacture high-barrier-to-entry transdermal drug delivery products and topical patches in our state-of-the-art laboratories and manufacturing facility. Our patches are designed with the patient in mind.
How We Do It
Our R&D team works collaboratively with our suppliers to create polymers and design combinations of excipients that improve the absorption of medications through the skin without having to resort to exotic permeation enhancers. Focused on what lies ahead, our team continues to explore methods to optimize delivery.
ProSolus is an experienced partner, with unrivaled transdermal and topical delivery prowess. Our experts are committed to delivering a customized experience every step of the way concept through completion. Whether you need formulation, development, and/or manufacturing support, we’ll provide sophisticated solutions tailored to your needs.